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Alkylphospholipids and alkylphosphocholines (APCs) are pro-
mising antitumor agents, which target the plasma membrane
and affect multiple signal transduction networks. We investi-
gated the therapeutic potential of erucylphosphohomocholine
(ErPC3), the first intravenously applicable APC, in human acute
myelogenous leukemia (AML) cells. ErPC3 was tested on AML
cell lines, as well as AML primary cells. At short (6–12 h)
incubation times, the drug blocked cells in G2/M phase of the
cell cycle, whereas, at longer incubation times, it decreased
survival and induced cell death by apoptosis. ErPC3 caused
JNK 1/2 activation as well as ERK 1/2 dephosphorylation.
Pharmacological inhibition of caspase-3 or a JNK 1/2 inhi-
bitor peptide markedly reduced ErPC3 cytotoxicity. Protein
phosphatase 2A downregulation by siRNA opposed ERK 1/2
dephosphorylation and blunted the cytotoxic effect of ErPC3.
ErPC3 was cytotoxic to AML primary cells and reduced the
clonogenic activity of CD34þ leukemic cells. ErPC3 induced a
significant apoptosis in the compartment (CD34þ CD38Low/Neg
CD123þ ) enriched in putative leukemia-initiating cells. This
conclusion was supported by ErPC3 cytotoxicity on AML blasts
showing high aldehyde dehydrogenase activity and on the
side population of AML cell lines and blasts. These findings
indicate that ErPC3 might be a promising therapeutic agent for
the treatment of AML patients.
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published online 4 March 2010
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Introduction
Two groups of antitumor drugs have been studied in the
past, which act on cellular membranes. Group 1 is based on the
structure of phospholipid molecules, the alkylphospholipids
(APLs). They contain phosphate esters of glycerol. The study of
APLs in vitro and the results on molecular mechanisms of cell
regulation and growth inhibition have strongly contributed to
the understanding of these molecules as possible antineoplastic
drugs. Edelfosine is the lead compound for this class of drugs.1
Group 2, however, are structurally less complex molecules.
They are simply phosphocholine esters of long-chain alcohols,
do not contain glycerol as structural element2 and are referred to
as alkylphosphocholines (APCs). APLs and APCs easily insert in
the plasma membrane and by doing so they inhibit phospholipid
turnover. The primary membrane domain targeted by APLs and
APCs are lipid rafts.3,4 APLs and APCs downregulate signaling
pathways, which are important for survival such as phosphatidyl-
inositol 3-kinase (PI3K)/Akt and mitogen-activated protein
kinase kinase/extracellular signal-regulated kinase (MEK/ERK),5,6
whereas they upregulate c-Jun N-terminal kinase (JNK) signaling,
which then promotes apoptosis.1 Edelfosine displayed consider-
able antitumor activity in preclinical models in both mouse
and rat, but much less so in the clinic. Thus, the only clinical
application of edelfosine was for purging bone marrow in
autologous bone marrow transplantation in acute myelogenous
leukemia (AML) patients.7 This application was based on the
observation that edelfosine selectively killed leukemic cells,
while sparing normal bone marrow cells both in vitro and in
a murine model in vivo.8,9
Miltefosine, the lead compound of APCs, has been approved
for the topical treatment of skin metastases in breast cancer and
the oral treatment of leishmaniasis.10 Perifosine is a miltefosine
analog that has been tested, either alone or in combination with
other drugs, in several type I/II clinical trials against tumors,
which included head and neck carcinoma, prostate cancer,
melanoma, multiple myeloma (MM) and AML.11 Some promis-
ing results have been observed in MM patients, who were
administered perifosine in combination with dexamethasone
and/or bortezomib.12 Moreover, recent findings have high-
lighted that perifosine, at variance with chemotherapeutic drugs,
could target putative cancer stem cells in vivo in breast tumor
xenografts.13 Perifosine has been tested in preclinical models of
AML in which it displayed a cytotoxic affect and synergized
with chemotherapeutic drugs and TRAIL.14,15 A major disadvan-
tage of perifosine is its poor gastrointestinal tolerability after
oral administration, which leads to insufficient plasma levels for
systemic cancer treatment. However, intravenous application of
perifosine is impossible due to intravascular hemolysis and
thrombophlebitis.1 These important limitations for oral dosing
could be overcome by compounds displaying longer alkyl
chains with cis-monounsaturation. Erucylphosphohomocholine
(ErPC3) is an APC displaying one cis-double bond in the
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alkyl chain with 22 carbon atoms, which could be applicable
intravenously in animals and displayed a high efficacy against
tumor models in vivo and in vitro.16,17 Recently, the in vitro
cytotoxic effect of ErPC3 in AML cells has been documented.18
In this study, we have further investigated the mechanisms that
could underlay ErPC3 cytotoxicity in AML cells. We demon-
strated that ErPC3 activated JNK 1/2. ErPC3 dephosphorylated
ERK 1/2 through a mechanism involving protein phosphatase 2A
(PP2A). Both JNK 1/2 inhibition by a synthetic peptide and PP2A
downregulation by short interfering RNA (siRNA) blunted ErPC3
cytotoxicity. Moreover, we also documented ErPC3 cytotoxicity
in primary AML populations, which are enriched in putative
leukemia-initiating cells (LICs). Overall, our findings highlight
several mechanisms that could explain ErPC3 cytotoxicity in
AML cells, and suggest that ErPC3 might be a promising drug for
treatment of AML patients.
Materials and methods
Chemicals and antibodies
The Cell Viability kit I (3-[4, 5-dimethylthiazol-2-yl]-2,
5-diphenyltetrazolium bromide, or MTT), Annexin V–fluorescein
isothiocyanate (FITC) and Annexin V–phycoerythrin (PE) staining
kits were from Roche Applied Science (Penzberg, Germany).
The p110a PI3K inhibitor (compound 15e or [3-[4-(4-morpho-
linyl)thieno[3,2-d]pyrimidin-2-yl]-phenol) was from Alexis Bio-
chemicals (Lausen, Switzerland). The MEK inhibitor CI-1040
and KO143 were from Axon Medchem BV (Groningen, The
Netherlands). The Aldefluor kit was from StemCell Technologies
(Vancouver, BC, Canada). The JNK 1/2 inhibitor peptide was
from BioMol International (Plymouth Meeting, PA, USA). For
western blot analysis, all the antibodies were from Cell Signaling
Technology (Beverly, MA, USA), except for the antibodies to
protein phosphatase 1 (PP1) and Ser 657 p-protein kinase C
(PKC) a, which were from Millipore/Upstate (Billerica, MA,
USA). For flow cytometric analysis, rabbit monoclonals to
Ser 473 p-Akt, Thr 202/Tyr 204 p-ERK 1/2 (both AlexaFluor 647-
conjugated), Thr183/Tyr 185 p-JNK and Ser p-BCL2 (AlexaFluor
488-conjugated) were from Cell Signaling Technology. R-PE-
Cyanine-7 (PC7)-conjugated anti-CD34, FITC- or PE-conjugated
anti-CD38, and phycocyanin-5 (PC5)-conjugated anti-CD123
(all mouse monoclonal IgGs) were from Beckman Coulter
Immunology (Miami, FL, USA). PE-conjugated anti-rabbit IgG
was from Sigma-Aldrich (St Louis, MO, USA). PE-conjugated
antibody to ATP-binding cassette (ABC) G2 membrane transpor-
ter was from Millipore. For immunocytochemistry experiments,
anti-phosphatidylinositol 3,4,5 trisphosphate (PIP3) monoclonal
antibody from Echelon Biosciences (Logan, UT, USA) was used.
Cell culture
THP1, HL60 and NB4 AML cells were exponentially grown in
RPMI 1640 medium supplemented with 10% heat-inactivated
fetal calf serum (FCS). Mouse Ba/F3 cells expressing mutant
(activated) p110a PI3K were cultured as previously described.19
Patients
Samples were obtained from patients at presentation of AML
at the Policlinico S. Orsola-Malpighi Hospital, Bologna, Italy.
Informed consent was obtained from all patients before receiving
the samples, according to the Institutional guidelines. Bone
marrow mononuclear cells were isolated by Ficoll-Paque
(Amersham Biosciences, Little Chalfont, Buckinghamshire, UK)
density-gradient centrifugation. The AML cases were defined
according to the classification of the French–American–British
committee. Percentage of blasts in the samples ranged between 75
and 91% and was determined by flow cytometry immunostaining.
Colony assay of CD34þ cells from cord blood or AML
patients
Healthy CD34þ cells were obtained from cord blood. Healthy
and leukemic CD34þ cells were isolated using immunomagnetic
cell separation (Miltenyi Biotec, Bergisch Gladbach, Germany)
and clonogenic assays were performed as described elsewhere.14
Cell growth analysis by MTT assay
An MTT assay was used to analyze cell growth and viability, as
previously described.14
Whole-cell lysate preparation and western blot analysis
This was performed according to standard techniques.20 Briefly,
cells were lysed and cell debris was removed by centrifugation at
13 000 r.p.m. for 15 min at 4 1C in a microfuge. Protein super-
natants (40mg of protein) were separated on SDS–polyacrylamide
gel electrophoresis and electro-transferred to nitrocellulose
membranes. Membranes were incubated overnight at 4 1C with
primary antibodies. They were then incubated with horseradish
peroxidase-conjugated secondary antibodies diluted 1:2000 in
5% non-fat dry milk in phosphate-buffered saline (PBS, pH 7.4)–
Tween 20 for 1 h at room temperature. Antibody binding was
detected by the SuperSignal West Pico Chemiluminescent
Substrate (Pierce Biotechnology, Rockford, IL, USA).
Immunofluorescence staining
This was performed as previously described,21–23 using an
antibody to PIP3.24
Quantitive reverse transcriptase PCR for p110 PI3K
isoforms
This was performed as described elsewhere,25 using primers
for p110 PI3K isoforms purchased from Applied Biosystems
(Foster City, CA, USA). Glyceraldehyde 3-phosphate dehydro-
genase was used as a control (for example, a constitutively
expressed housekeeping gene).
Transient protein downregulation by siRNA
siRNA targeting PP2A/C subunit mRNA (target sequence: 50-GA
ATCCAACGTTCAAGAGG-30) and negative control (scrambled
sequence) were purchased from Dharmacon Research Inc
(Lafayette, CO, USA). The target sequence against PP2A/C was
chosen by the web-based search program, and the lack of
homology to any other gene was confirmed by a BLAST search
(National Center for Biotechnology Information, National
Institutes of Health, USA). Transfection of cells was performed
using the Amaxa system (Amaxa, Cologne, Germany). Briefly,
106 cells in 100ml of medium were mixed with 3 mg of siRNA
and transferred to an Amaxa-certified cuvette. For transfection,
the program V-01 was used for THP1 cells, whereas for AML
primary cells, we used program U-15.26 For both cell types, the
Amaxa transfection kit V was used. Cells were examined for
downregulation of the target gene and subsequent important
effects, 48 h after transfection.
Flow cytometric cell cycle and apoptosis analysis
Cell-cycle analysis was carried out on propidium iodide (PI)-
stained samples,27 whereas apoptosis was studied by the
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binding of Annexin V–FITC to phosphatidylserine exposed on
the cell membrane.25 Samples were analyzed on a EPICS XL
flow cytometer (Beckman Coulter Immunology).
Quadruple flow cytometric analysis with CD34, CD38,
CD123 and Annexin V for apoptosis analysis
Cells were incubated with PC7-conjugated anti-CD34, FITC- or
PE-conjugated anti-CD38, PC5-conjugated anti-CD123 and
PE-conjugated Annexin V for 15 min at room temperature. In
some cases, they were processed for intracellular staining with
a rabbit monoclonal antibody to Thr183/Tyr 185 p-JNK 1/2,
which was recognized by a PE-conjugated secondary antibody
raised in goat, or an AlexaFluor 488-conjugated anti-Ser 70
p-BCL2, essentially as reported by others.28 Samples were
analyzed on dual-laser FC500 flow cytometer (Beckman Coulter
Immunology). Appropriate anti-isotypic control antibodies were
used to establish the specificity of quadruple staining.
Flow cytometric Aldefluor cell analysis for ALDH
activity in AML patient cells
Briefly, AML cells were resuspended in the Aldefluor assay
buffer, containing the aldehyde dehydrogenase (ALDH) sub-
strate, Bodipy-aminoacetaldehyde (1 mM), according to the
manufacturer. In each experiment, a sample of cells was stained
under identical conditions with the specific ALDH inhibitor
diethylaminobenzaldehyde (50 nM) as negative control.29 Alde-
fluor fluorescence was excited at 488 nm, and fluorescence
emission was detected using a standard FITC 530 nm band-pass
filter30
Flow cytometric detection of AML SP cells
Cells were resuspended at 1 106 per ml in RPMI 1640/2% FCS.
Hoechst 33342 dye was added at a final concentration of
5mg/ml in the presence or the absence of verapamil (100 mM), or
fumitremorgin c (10 mM), or KO143 (0.1 mM). Samples were
incubated at 37 1C for 90 min, then washed with PBS/2% FCS,
and resuspended in PBS/2% FCS. In some experiments, cells
were prestained with PE-conjugated anti-ABCG2 monoclonal
antibody. After a 20-min incubation, cells were washed with
PBS/2% bovine serum albumin and then processed for Hoechst
33342 staining. Control samples for anti-ABCG2 were run with
an irrelevant isotypic PE-conjugated antibody. Samples were
analyzed with a Cell Lab Quanta SC (Beckman Coulter
Immunology) flow cytometer equipped with ultraviolet lamp
and 488 solid-state laser. The Hoechst 33342 dye was excited at
366 nm. Side population (SP) cells were gated by FL1/FL3
histogram, while ABCG2 staining was evaluated by FL2
channel.31
Statistical evaluation
The data are presented as mean values±s.d. Data were
statistically analyzed using Dunnett’s test after one-way analysis
of variance at a level of significance of Po0.05 vs control
samples.
Results
ErPC3 has cytotoxic proapoptotic activity on AML cell
lines
As APLs and APCs are known for targeting both PI3K/Akt and
MEK/ERK signaling, the activation states of these two networks
in AML cell lines were first investigated. Although HL60 and
NB4 displayed only activated ERK 1/2, THP1 cells had both
activated Akt and ERK 1/2, as documented by western blot
analysis (Figure 1a). Then, the cytotoxic effect of ErPC3 on AML
cell lines was analyzed, using increasing concentrations of the
drug. After 24 h, the rates of growth were measured using MTT
assays. Cell lines displayed an IC50 for ErPC3 ranging from
4.9 mM (THP1) to 7.9 (HL60) to 13.1mM (NB4) (Figure 1b). The
effect of ErPC3 on cell-cycle progression was investigated next.
Flow cytometric analysis of PI-stained THP1 cells treated with
10 mM ErPC3 documented an increase in G2/M phase cells and a
decrease in G1 phase cells, which was already evident after 6 h
of incubation with the drug and became more pronounced at
12 h (Figure 1c). It was next investigated whether ErPC3
cytotoxicity was related to apoptosis, using Annexin V–FITC/PI
staining and flow cytometry. After treatment of THP1 cells with
ErPC3 for 24 h, there was a concentration-dependent increase in
early apoptotic (Annexin V–FITC positive only) and mid-late
apoptotic (Annexin V–FITC/PI positive) cells. Both a caspase-9
and a caspase-3 inhibitor strongly reduced apoptosis (Figure 1d).
Western blot analysis documented that cleavage of apical
caspase-9 and of effector caspase-3 already occurred at 3 mM
ErPC3 (not shown).
Overall, these findings demonstrated that ErPC3 reduced the
growth of AML cell lines and that this effect was due to both
cell-cycle arrest and apoptosis.
ErPC3 induces JNK 1/2 activation in THP1 cells
At 3 mM, ErPC3 rapidly and transiently activated JNK 1/2, as
indicated by western blot analysis (Figure 2a). The use of a
blocking peptide to JNK 1/232 documented that JNK 1/2
activation was important for ErPC3-mediated cytotoxicity, as
the inhibitor peptide significantly increased THP1 cell survival
in a concentration-dependent manner (Figure 2b). As a control,
we demonstrated using western blot that the blocking peptide
was able to prevent phosphorylation of ELK1, a JNK 1/2
substrate,33 elicited by anisomycin, a well-established activator
of JNK 1/2 in THP1 cells14 (Figure 2c).
ErPC3 affects PI3K/Akt signaling in THP1 cells
Western blot analysis with antibodies to either Thr 308 or Ser
473 p-Akt, demonstrated a marked decrease in these p-Akt
forms in response to ErPC3 after 24 h of treatment (Supplemen-
tary Figure 1a). Dephosphorylation on both Thr 308 and Ser 473
p-Akt residues was evident at 10mM ErPC3, whereas at 20mM
ErPC3, no p-Akt was detectable. However, we also detected a
reduction in the amount of Akt, which became apparent already
at 10 mM, whereas at 20 mM, no Akt was visible. The loss of Akt
following ErPC3 treatment was abolished by the inhibition of
caspase-3 activity with Z-VAD-FMK, suggesting it was due to a
caspase-3-dependent mechanism (Supplementary Figure 1b), as
previously reported by our group in lymphoblastic leukemia
cells.20 ErPC3 also increased the expression levels of p110a
PI3K in a concentration-dependent manner, but not those of
either p110b or p110d PI3K (Supplementary Figure 1a).
Increased p110a PI3K expression was due to enhanced gene
expression, as documented by quantitative reverse transcriptase
PCR (Supplementary Figure 1c). This upregulation of p110a
PI3K had functional consequences, because ErPC3 increased the
amount of the end product of PI3K, PIP3, as demonstrated by
immunofluorescence staining with a monoclonal antibody to
PIP3.34 Remarkably, compound 15e, a p110a PI3K-selective
inhibitor,35 prevented the increase in PIP3 levels in response to
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ErPC3 treatment, but not under basal conditions (Supplementary
Figure 1d). These findings were consistent with the notion
that, in THP1 cells, p110d PI3K is the most important isoform
for regulating downstream signaling events under basal
conditions.36
Akt dephosphorylation/cleavage in THP1 cells was detected
at a concentration (10 mM ErPC3), which was well above the IC50
for this drug in this cell line (around 5 mM, see Figure 1a). This
observation suggested that Akt downmodulation could not be a
major factor in determining cell sensitivity to ErPC3. However,
previous results have documented that PI3K/Akt activation
rendered neoplastic cells more sensitive to perifosine.37 To
establish if PI3K/Akt activation would indeed sensitize hemato-
poietic cells to ErPC3, we took advantage of mouse Ba/F3 cells
overexpressing mutant (activated) forms of p110a PI3K. These
cells display elevated, constitutive Akt activation, are inter-
leukin-3 independent and are leukemogenic when transplanted
in sublethally irradiated Balb/C mice.19 However, as presented
Figure 1 ErPC3 is cytotoxic to AML cell lines. (a) Western blot analysis documenting PI3K/Akt and/or MEK/ERK activation in AML cell lines.
Protein (40 mg) from whole-cell extracts were separated by SDS–polyacrylamide gel electrophoresis, blotted to nitrocellulose membranes and
probed with antibodies. b-Actin served as a loading control. (b) MTT assays of AML cell lines treated with ErPC3 for 24 h. Results are the mean of at
least three different experiments±s.d. The asterisks indicate statistically significant difference (Po0.01) with respect to untreated cells. (c) Cell-
cycle analysis of PI-stained THP1 cells. The histograms are representative of three separate experiments that were performed in triplicate. (d) Flow
cytometric analysis of Annexin V–FITC/PI-stained THP1 cells treated with ErPC3 for 24 h. The percentages of early apoptotic cells (Annexin
V–FITCþ /PI; lower right quadrant) and late apoptotic/necrotic cells (Annexin V–FITCþ /PIþ ; upper right quadrant) are indicated. The histograms
are representative of three separate experiments that were performed in triplicate. For experiments with caspase inhibitors (Z-DEVD-FMK for
caspase-3 and AC-LEHD-CHO for caspase-9), the cells were preincubated with the chemicals (20 mM) for 2 h before ErPC3 treatment.
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in Supplementary Figure 2a, MTT assays documented that Ba/F3
cells overexpressing mutant p110a PI3K were not more sensitive
to ErPC3 than control (transfected with the empty vector only)
cells. Western blot analysis demonstrated Akt phosphorylation
in the former, but not in the latter Ba/F3 cells (Supplementary
Figure 2b). Overall, these findings suggested that Akt activation
could not be considered a major factor that influenced
hematopoietic cell sensitivity to ErPC3.
ErPC3 affects MEK/ERK signaling in THP1 and HL60
cells
In THP1 cells, ERK 1/2 was already completely dephosphory-
lated at 3 mM ErPC3, whereas no MEK1/2 dephosphorylation was
detectable even at the highest drug concentration tested (20 mM).
Similar results were observed with HL60 cells, even if in
this case MEK dephosphorylation was detected at 10mM ErPC3
(Figure 3a). This observation prompted us to investigate
mechanisms, other than MEK 1/2 inhibition, which could
explain the decreased levels of p-ERK 1/2 in response to
ErPC3. If THP1 cells, in addition to ErPC3, were treated with
okadaic acid (300 nM), an inhibitor of both PP1 and PP2A, the
decrease in ERK 1/2 phosphorylation was completely reversed
(Figure 3b). This suggested that ErPC3 activated protein
phosphatases, which could then be involved in dephosphory-
lating p-ERK 1/2. As there are reports indicating that PP2A
is sometimes involved in ERK 1/2 dephosphorylation,38–40 we
downregulated the catalytic subunit of PP2A (PP2A/C) by
siRNA,41 then we analyzed whether downmodulation affected
THP1 cell sensitivity to ErPC3. Western blot analysis documen-
ted that specific siRNA to PP2A/C reduced its expression by
B75%, whereas a control (scrambled) siRNA had no effect
(Figure 3c). In addition, both siRNAs did not affect PP1
expression levels. MTT assays demonstrated that in cells
with downregulated PP2A/C expression, the cytotoxic effect of
ErPC3 was significantly blunted, whereas in cells treated with
scrambled siRNA, ErPC3 cytotoxicity was comparable with
control cells (Figure 3c). Western blot analysis demonstrated
that PP2A/C downmodulation indeed prevented ERK 1/2
dephosphorylation by ErPC3 (Figure 3d).
A downstream target of MEK/ERK signaling, which is
important for cell survival, is BCL2. BCL2 phosphorylation on
Ser 70 blocks its antiapoptotic function.42. As it is established
that BCL2 phosphorylation on Ser 70 is regulated not only by
ERK 1/2 and PP2A41,43 but also by the stress-activated JNK,42 it
was important to investigate whether ErPC3 could indeed
modulate the levels of p-BCL2. As documented by western
blotting, ErPC3 decreased p-BCL2 phosphorylation levels on Ser
70 (Figure 3e). However, in cells exposed to PP2A/C-specific
siRNA, but not in those treated with control siRNA, ErPC3 was
ineffective in decreasing p-BCL2 levels. A decrease in p-BCL2
was also observed in both THP1 and HL60 cells treated with a
specific MEK inhibitor (CI-1040, 0.5mM), but not in those
exposed to the JNK 1/2 inhibitor peptide (Figure 3f). Overall,
these findings indicated important roles for PP2A and ERK 1/2
signaling in the regulation of p-BCL2 levels in AML cells
treated with ErPC3, and suggested that ERK 1/2 is upstream of
BCL2. We also investigated the expression of other proteins
whose expression is under the control of MEK/ERK signaling
and which could be important for cell survival, including
BCL-XL, survivin and MCL1.44–46 However, in THP1 cells none
of these proteins decreased in response to ErPC3 treatment.
In contrast, ErPC3 upregulated proapoptotic Bim levels, consis-
tently with ERK 1/2 signaling inhibition47 (Figure 3f). Ba/F3 cell
clones displayed p-ERK 1/2; however, ErPC3 treatment resulted
in slight or no dephosphorylation (Supplementary Figure 2c).
This finding strengthened the contention that ERK 1/2 dephos-
phorylation is critical for the cytotoxic activity of ErPC3.
As PKCa can activate Raf,48 it might be that ErPC3 promoted
PP2A dephosphorylation of PKCa to suppress Raf-mediated
activation of MEK, as documented by others.49 Therefore, PKCa
phosphorylation was investigated in AML cell lines after
treatment with increasing concentrations of ErPC3. How-
ever, as shown in Supplementary Figure 2d, neither in THP1
nor in HL60 cells, ErPC3 exposure resulted in PKCa dephos-
phorylation on Ser 657. Actually, PKCa phosphorylation
levels increased, in agreement with our own previous findings
obtained with perifosine.15 We did not detect p-PKCa in NB4
cells.
Figure 2 ErPC3 activates JNK 1/2 in THP1 cells. (a) Western blot
analysis for p-JNK 1/2 and JNK 1/2 in THP1 cells treated with 3 mM
ErPC3 for increasing periods of time. b-Actin served as a loading
control. (b) MTT assays of AML cell lines treated with ErPC3 (3mM for
24 h) in the absence or in the presence of a JNK 1/2 inhibitor peptide
(JNKi). Results are the mean of three different experiments±s.d. The
asterisks indicate statistically significant difference (Po0.05) with
respect to untreated cells. (c) Western blot analysis for p-ELK1 and
ELK1 in THP1 cells challenged with anisomycin. Cells were treated
with the chemical (10 mg/ml) for 1 h. In case of JNK 1/2 peptide
inhibitor (JNKi) treatment, cells had been preincubated with the
peptide (1mM) for 2 h before incubation with anisomycin. An antibody
specific to Ser 383 p-ELK1 was used. CTRL: untreated cells.
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ErPC3 is cytotoxic to primary AML cells and inhibits
clonogenic activity of leukemic CD34þ cells
The efficacy of ErPC3 was then analyzed on bone marrow
samples obtained from 13 patients with AML. In these samples,
activation of PI3K/Akt and MEK/ERK signaling pathways was
analyzed using quantitative flow cytometry. A ratio of fluores-
cence intensity 42.0 was considered positive for pathway
activation.50 In these samples, MTT assays (72 h) documented
an IC50 for ErPC3 ranging from 7.5 to 14.5 mM (Table 1).
To formally prove that a PP2A-dependent mechanism was
causal to the cytotoxic effect of ErPC3 also in primary leukemic
cells, we silenced the PP2A/C expression in AML cells by
transfection of specific siRNA and assayed transfected cells for
apoptosis. Supplementary Figure 3a shows that AML cells could
be efficiently transfected by PP2A/C siRNA. The downmodula-
tion of PP2A/C significantly reduced AML blast sensitivity to
15mM ErPC3 after a 72-h incubation with the drug (Supplemen-
tary Figure 3b). ErPC3 did not influence clonogenic activity of
healthy CD34þ cells from cord blood; however, in leukemic
CD34þ cells, ErPC3 exhibited a statistically significant inhibi-
tory effect (Figure 4a).
ErPC3 induces apoptosis in the CD34þ CD38Low/Neg
CD123þ AML blast subset in which it activates JNK 1/2
and dephosphorylates p-BCL2
A key issue in AML therapy is to target the compartment of
LICs, which are thought to be involved in AML chemoresistance
and relapse.51 The CD34þ CD38Low/Neg CD123þ population
has been previously reported as being a cell compartment
enriched in LICs28. AML samples were treated with 15mM
ErPC3, and apoptosis was analyzed by quadruple color flow
Figure 3 ErPC3 affects MEK/ERK signaling in THP1 and HL60 cells through PP2A. (a) Western blot analysis for p-MEK 1/2, MEK 1/2, p-ERK 1/2
and ERK 1/2 expression levels in response to increasing concentrations of ErPC3 administered for 24 h. (b) Western blot analysis documenting that
the protein phosphatase inhibitor, okadaic acid, counteracted the ErPC3-elicited p-ERK 1/2 dephosphorylation. THP1 cells were incubated with
ErPC3 for 24 h. (c) PP2A/C downregulation by means of siRNA blunts the cytotoxic effect of ErPC3. MTT assays of THP1 cells treated with ErPC3 for
24 h. Results are the mean of at least three different experiments±s.d. The asterisks indicate statistically significant difference (Po0.01) with
respect to untreated cells. CTRL siRNA: control (scrambled) siRNA. The blot in panel c documents decreased PP2A/C expression in cells treated for
48 h with siRNA specific to PP2A/C. Protein levels were quantified using the Image J software (http://rsbweb.nih.gov/ij/). Band intensities of control
were normalized to 1, and treated samples were expressed as fraction of control.20 (d) Western blot analysis demonstrating that siRNA to PP2A/C
reverses p-ERK 1/2 dephosphorylation caused by ErPC3 (24 h). CTRL siRNA: scrambled siRNA. (e) Western blot analysis documenting that, in
THP1 cells with downmodulated PP2A/C expression, p-BCL2 was not dephosphorylated and caspase-3 was cleaved less in response to ErPC3
treatment (24 h) when compared with control cells or cells incubated with control (CTRL) siRNA. (f) Western blot analysis showing that, in both
THP1 and HL60 cells, p-BCL2 levels were under the control of MEK/ERK, but not JNK signaling. Cells were treated for 24 h with CI-1040 (0.5mM,
a MEK inhibitor) or the JNK 1/2 inhibitor peptide (1mM). (g) Western blot analysis for antiapoptotic proteins in THP1 cells incubated for 24 h in the
presence of increasing concentrations of ErPC3.
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cytometry.28 An antibody to p-JNK 1/2 documented that ErPC3
activated JNK 1/2 also in this AML cell subset (Figure 4b). Using
Annexin V-PE staining in this specific subpopulation, it was
demonstrated that ErPC3 induced significant concentration-
dependent apoptosis in all the six samples tested. Apoptosis
ranged between 6 and 9% in control samples vs 25 and 31% in
treated (15 mM ErPC3) samples. It can be noted that the JNK 1/2
peptide inhibitor significantly reduced apoptosis in this im-
mature leukemic cell subpopulation (Figure 4c). Moreover, the
same technique highlighted that ErPC3 (15mM) dephosphory-
lated Ser 70 p-BCL2 in this AML cell subset (Figure 4d). These
results indicated that ErPC3 may target a cell compartment
enriched in putative LICs and that JNK activation is important for
ErPC3 cytotoxicity also in AML primary cells.
ErPC3 targets both primary AML cells with high levels of
ALDH and the SP of AML cell lines and patients
Cells with high levels of ALDH are also considered to be
enriched in LICs.29,52,53 It was therefore investigated whether
ErPC3 could target this subpopulation using Aldefluor-stained
samples from six AML patients. Diethylaminobenzaldehyde, an
inhibitor of ALDH, was used to demonstrate the specificity of
the staining. The number of ALDHþ cells varied greatly in each
of these AMLs (Figure 5a), but in all cases a very pronounced
and statistically significant decrease in the number of these
cells was observed after 24 h of incubation with 15 mM ErPC3
(Figures 5a–b). Moreover, as a further control, we repeated the
experiments using samples that were double stained for CD34
and ALDH, as it has been reported that CD34/ALDHþ cells are
normal erythroid progenitors.54 Thus, we could assess that
ErPC3 indeed targeted a CD34þ /ALDHþ leukemic subpopula-
tion (not shown).
Finally, we sought to demonstrate whether ErPC3 could target
the SP of THP1 and HL60 cells, as this subpopulation, which
overexpresses ABCG2 (also referred to as Breast Cancer
Resistance Protein or BRCP),55,56 is thought to share some
properties of tumor-initiating cells.57,58 The SP of THP1 and
HL60 cells was identified by the live-cell DNA-binding dye,
Hoechst 33342. As a control, Hoechst 33342 staining could be
inhibited after incubation with the broad-specificity ABC
membrane transporter inhibitor, verapamil, or the selective
ABCG2 transporter inhibitor, fumitremorgin c. A concentration-
dependent decrease in the amount of SP cells was evident in
samples treated with ErPC3 for 24 h (Figures 6a,b). Expression of
ABCG2 on THP1 SP cells was documented by double staining
with Hoechst 33342 and a PE-conjugated antibody, which
recognizes an extracellular epitope of the transporter (Figure 6c).
The bulk of the THP1 and HL60 cell population did not display
any positivity for ABCG2 (data not shown). It was next
investigated whether ErPC3 was also effective in reducing the
SP of eight AML patients. In this case, to identify the SP we used
the fumitremorgin c analog, KO143 (0.1 mM), which is more
potent than fumitremorgin c and is nontoxic at effective in vitro
and in vivo concentrations.59 The proportion of SP cells in bone
marrow samples varied widely among patients, from 3.0 to
12.1% (average 6.85±3.49), in agreement with others.57 After
ErPC3 treatment (15mM for 24 h), the SP of AML primary cells
was not detectable anymore. Staining for ABCG2 confirmed the
expression of this transporter also in the SP of AML patients
(Figure 6d).
Discussion
ErPC3 is an APC, a class of antitumor agents that differs from
APLs, as APCs do not contain glycerol as structural element.
In this study, we have addressed the efficacy of ErPC3 in
decreasing cell survival of AML cell lines and blasts. We have
demonstrated that ErPC3, in a dose-dependent manner, was
cytotoxic to AML cell lines. In THP1 cells, ErPC3 induced a
G2/M block and then apoptosis. An inhibitor of caspase-9 was
less effective than an inhibitor of caspase-3 in reducing apop-
tosis. This observation is consistent with the fact that ErPC3
activated other apical caspases, including caspase-8 and -10
(not shown). ErPC3 also induced a transient activation of JNK 1/2.
The relevance of JNK 1/2 upregulation for ErPC3 cytotoxicity was
demonstrated by the use of a JNK 1/2 inhibitor peptide, which
increased cell survival, and this was consistent with the notion
that JNK signaling was very important for apoptosis induced by
ErPC3 in glioblastoma cells.60 The peptide we used in our study
is one of the most selective JNK 1/2 inhibitors, which are
currently available, as it inhibits interactions between JNK 1/2
and downstream targets.33 It is worth mentioning here that a
transient JNK 1/2 activation has been previously observed with a
different APC, perifosine.25
In THP1 cells, we observed a dephosphorylation of Akt on
both Ser 473 and Thr 308, which became apparent at 10mM
ErPC3. However, Akt dephosphorylation was accompanied by
a decrease in total Akt, which was due to Akt cleavage. A novel
finding that emerged from our studies is that ErPC3 upregulated
the levels of p110a PI3K and its end product, PIP3. This could be
interpreted as a mechanism of defence implemented by the cells
against a proapoptotic insult. Nevertheless, increased PIP3
production did not result in increased phosphorylation levels
of Akt, and p110a PI3K inhibition with a selective inhibitor did
not increase ErPC3 cytotoxicity (data not shown), so that the
relevance of PIP3 upmodulation in response to ErPC3 treatment
needs to be further addressed.
ErPC3 (3 mM) completely dephosphorylated ERK 1/2 in both
THP1 and HL60 cells, whereas p-MEK 1/2 dephosphorylation
was undetectable in THP1 cells or detected at a much higher
Table 1 AML patients, activation status of signaling pathways and
efficacy of ErPC3
Patient FAB RFI p-AKT RFI p-ERK1/2 IC50 ErPC3 (mM)
1 M1 3.4 2.6 10.6±1.8
2 M0 3.8 3.9 9.8±1.5
3 M1 1.4 1.6 13.8±2.3
4 M2 1.5 3.7 9.1±1.9
5 M1 1.9 2.8 10.9±2.1
6 M4 5.8 2.2 9.6±1.5
7 M5 2.1 2.2 14.5±2.6
8 M4 1.5 4.4 8.5±2.8
9 M4 2.3 2.6 10.5±1.9
10 M5 1.2 3.3 8.5±1.4
11 M2 1.1 4.1 7.5±1.7
12 M0 2.8 1.5 13.2±2.7
13 M0 2.5 1.7 13.4±3.1
Abbreviations: AML, acute myelogenous leukemia; ErPC3, erucyl-
phosphohomocholine; FAB, French–American–British; MTT, 3-[4,
5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide; RFI, ratio of
fluorescence intensity.
AML blasts were isolated from patient bone marrow. They were then
stained for Ser 473 p-Akt or p-ERK 1/2 using antibodies conjugated to
AlexaFluor 647. We analyzed RFI between the mean fluorescence
intensity (MFI) of the stained cells and the MFI of the isotypic control.
Cells were considered as positive if the RFI was 42. For calculation of
the IC50, cells were incubated in triplicate with ErPC3 for 72 h, then
MTT assays were performed.
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Figure 4 ErPC3 reduces the clonogenic activity of leukemic CD34þ cells and induces apoptosis in the CD34þ , CD38Low/Neg, CD123þ leukemic
cell compartment. (a) Clonogenic assays. Cord blood or leukemic patient’s CD34þ cells were seeded in a semisolid methylcellulose medium
containing GM-CSF, interleukin-3 and -6 for 14 days. The x axis indicates the number of colonies per view (observation at  25 under an Olympus
light microscope, Olympus, Tokyo, Japan). Results are the mean±s.d. from three different experiments. (b) Blast cells from AML patients were
incubated for 48 h in the presence of ErPC3, and then subjected to flow cytometric analysis with antibodies to CD38-FITC, CD34-PC7, CD123-
PC5, and an unconjugated primary antibody to JNK 1/2, which was followed by a PE-conjugated secondary antibody. Results are shown for patient
2. (c) The CD34þ CD38Low/Neg CD123þ subpopulation was then analyzed for Annexin V–PE staining. Annexin V–PE-positive cells in the selected
CD34þ CD38Low/Neg CD123þ compartment are shown for patient 4. Note how a JNK 1/2 inhibitor peptide (1mM) decreased ErPC3-dependent
apoptosis. (d) ErPC3 dephosphorylates Ser 70 p-BCL2 in the CD34þ CD38Low/Neg CD123þ leukemic subpopulation. Experimental details are as in
b, except that PE-conjugated anti-CD38 and AlexaFluor 488-conjugated anti-Ser 70 p-BCL2 antibodies were used. Results are shown for patient 7.
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ErPC3 concentration (10mM) in HL60 cells. Our findings suggest
that ERK 1/2 dephosphorylation was due to activation of PP2A,
as both the protein phosphatase inhibitor okadaic acid and
siRNA downregulation of PP2A/C blocked ErPC3-dependent
ERK 1/2 dephosphorylation in THP1 cells. It is intriguing that a
cholesterol-regulated dual-specificity ERK 1/2 phosphatase,
composed of PP2A and the tyrosine phosphatase HePTP, has
been demonstrated to localize to lipid rafts.38 Considering that
ALPs and APCs target the lipid rafts, we could hypothesize that
ErPC3 activated this phosphatase complex, which would then
dephosphorylate ERK 1/2. In the absence of PP2A/C, the
complex could not form, so that ERK1/2 was not depho-
sphorylated. ERK 1/2 dephosphorylation was capable of
impinging on BCL2, as also this antiapoptotic protein was
dephosphorylated and inactivated in response to ErPC3 (or a
MEK inhibitor) treatment in THP1 cells. The relevance of
ERK 1/2 dephosphorylation to the ErPC3 cytotoxic effect was
also demonstrated by experiments carried out in Ba/F3 cell
clones, which were less sensitive to the drug than human AML
cell lines and did not display ERK 1/2 dephosphorylation. It can
be noted that ErPC3 did not cause caspase activation in Ba/F3
cells and there was no Akt cleavage in the clones (data not
shown). Nevertheless, HL60 and NB4 cells, which displayed
ERK 1/2, but not Akt phosphorylation, were less sensitive to
ErPC3 than THP1 cells, which have both activated ERK 1/2 and
activated Akt. This likely indicates that other factors are involved
in determining AML cell sensitivity to ErPC3.
ErPC3 negatively affected cell survival of AML blast cells.
Interestingly, also in primary AML cells, downmodulation of
PP2A/C by siRNA significantly blunted ErPC3 cytotoxicity. This
effect of ErPC3 on PP2A activity could be relevant for its
therapeutic development, as recent findings have highlighted
that PP2A expression levels are low in AML primary cells.61
Thus, it could be important to develop drugs that increase PP2A
activity.
ErPC3 did not negatively affect the clonogenic activity of
CD34þ cells from cord blood. In contrast, the clonogenic
activity of CD34þ cells from AML patients was significantly
impaired by ErPC3. It is now well demonstrated that only a small
subset of cells, referred to as LICs,51 are able to maintain the
leukemic cell pool in the long term. These cells are CD34þ ,
CD38Low/Neg, CD123þ , although not all the cells showing this
phenotype are probably true LICs. ErPC3 increased apoptosis in
this AML cell subpopulation. Using flow cytometry we were also
able to demonstrate that ErPC3 activated JNK 1/2 and depho-
sphorylated Ser 70 p-BCL2 in these cells and that JNK activation
had an important role in the apoptosis induced by ErPC3. As a
further proof that ErPC3 targets subpopulations that are enriched
in putative LICs, we documented that the drug decreased the
number of AML blasts with high levels of ALDH, and also
markedly diminished the number of AML cells displaying the SP
phenotype. Therefore, our results are fully consistent with two
recent reports that have shown that perifosine was able to target
SP cells in glioblastomas,56 as well as cells with cancer stem-cell
like properties in breast tumor xenografts.13 These important
properties of ErPC3 and perifosine are not always induced by
traditional chemotherapeutic agents. It is at present unclear
whether ErPC3 was cytotoxic to the SP cells or it simply blocked
the activity of ABCG2, as it has been previously documented
that membrane localization of ABCG2 in mouse bone marrow
cells was dependent on Akt activity.62 Nevertheless, ErPC3
decreased the SP of THP1 cells even at a concentration (3 mM) in
which it did not affect Akt amount/phosphorylation. Moreover,
ErPC3 targeted the SP of HL60 cells that do not display Akt
activation. These observations suggest that ErPC3 could be
directly cytotoxic to the SP cells. However, additional experi-
ments are required to further address this issue.
Our findings suggest that Akt activation does not confer
additional sensitivity to ErPC3 in mouse hematopoietic cells.
The MTT assays performed in AML primary cells would indicate
that ERK 1/2 activation is critical for ErPC3 sensitivity, as cells
with low levels of p-ERK 1/2 generally displayed a higher IC50
for ErPC3; however, analysis of a larger cohort of patients is
required. In addition, the levels and activation of JNK 1/2 in
response to ErPC3 should be analyzed in a larger number of
AML patients. JNK 1/2 could be a critical mediator of AML
patient sensitivity to various drugs, as has been recently
established for anthracyclines.63 The role of ERK 1/2 in drug
resistance is now firmly established.64 In this connection, it is
important to emphasize that ErPC3 synergizes in vitro with
chemotherapeutic drugs commonly used for treating AML
Figure 5 Effect of ErPC3 ALDHþ cells in AML patients. (a) ALDHþ
cells in four different AML patients, after incubation for 48 h in the
presence of 15 mM ErPC3. Bodipy-aminoacetaldehyde was used as the
ALDH substrate. In each experiment, a sample of cells was stained
under identical conditions with the specific ALDH inhibitor diethyla-
minobenzaldehyde (DEAB) (50 nM) as negative control. Results are the
mean of three different experiments±s.d. The asterisks indicate
statistically significant difference (Po0.01) with respect to untreated
cells. CTRL: untreated cells. (b) Flow cytometric analysis of ALDHþ
cells in two representative AMLs. Experimental conditions were as in
panel a. ALDHþ cells, which disappeared in the presence of DEAB,
were gated. Square, portion of ALDHþ cells that were gated for
analysis.
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Figure 6 ErPC3 reduces the amount of SP cells. (a and b) THP1 (a) and HL60 (b) cells were stained with Hoechst 33342 dye (5mg/ml) in the
presence or absence of either verapamil (100mM) or fumitremorgin c (10mM), then analyzed by flow cytometry. The SP, which disappeared in
the presence of either verapamil or fumitremorgin c, was gated and shown as a percentage of the whole viable cell population. Incubation in the
presence of increasing concentrations of ErPC3 was for 24 h. (c) Flow cytometric analysis of THP1 cells double stained with Hoechst 33342 and a
PE-conjugated antibody to ABCG2. Black histograms: negative control (irrelevant antibody); white histograms: cells positive for ABCG2. (d) Flow
cytometric analysis of the SP and ABCG2 expression in patient 2. Bone marrow mononuclear cells were incubated with ErPC3 (15 mM for 24 h). For
experimental details, see panels a–c in this figure. KO143 was used at 0.1mM. In a–d, one representative of three different separate experiments is
shown. CTRL: cells stained with Hoechst 33342 only.
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patients.18 ErPC3 has been studied in a phase I dose escalation
trial at the University of Munich. Thereby, plasma steady state
levels of 10–20 mM ErPC3 after repeated intravenous application
have been reached without showing toxicity (data not shown).
These promising clinical data and our preclinical findings
showing significant apoptosis in AML cells at dose levels
of 15 mM ErPC3 strongly suggest that ErPC3 could be a valuable
drug for improving our arsenal for the treatment of AML
patients who still face a poor prognosis, especially those aged
X60 years.65
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